Logo image of MDCX

MEDICUS PHARMA LTD (MDCX) Stock Fundamental Analysis

NASDAQ:MDCX - CA58471K2020 - Common Stock

1.94 USD
-0.06 (-3%)
Last: 8/29/2025, 8:00:01 PM
1.9405 USD
+0 (+0.03%)
After Hours: 8/29/2025, 8:00:01 PM
Fundamental Rating

1

MDCX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 542 industry peers in the Biotechnology industry. MDCX has a bad profitability rating. Also its financial health evaluation is rather negative. MDCX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

MDCX had negative earnings in the past year.
In the past 5 years MDCX always reported negative net income.
MDCX had a negative operating cash flow in each of the past 5 years.
MDCX Yearly Net Income VS EBIT VS OCF VS FCFMDCX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

MDCX's Return On Assets of -195.00% is on the low side compared to the rest of the industry. MDCX is outperformed by 90.44% of its industry peers.
MDCX's Return On Equity of -319.45% is on the low side compared to the rest of the industry. MDCX is outperformed by 72.06% of its industry peers.
Industry RankSector Rank
ROA -195%
ROE -319.45%
ROIC N/A
ROA(3y)-358.98%
ROA(5y)-4285.53%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MDCX Yearly ROA, ROE, ROICMDCX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MDCX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MDCX Yearly Profit, Operating, Gross MarginsMDCX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

MDCX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for MDCX has been increased compared to 5 years ago.
There is no outstanding debt for MDCX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MDCX Yearly Shares OutstandingMDCX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
MDCX Yearly Total Debt VS Total AssetsMDCX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M

2.2 Solvency

Based on the Altman-Z score of -2.74, we must say that MDCX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of MDCX (-2.74) is comparable to the rest of the industry.
MDCX has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.07, MDCX is doing worse than 62.50% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z -2.74
ROIC/WACCN/A
WACCN/A
MDCX Yearly LT Debt VS Equity VS FCFMDCX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5M -10M

2.3 Liquidity

A Current Ratio of 2.73 indicates that MDCX has no problem at all paying its short term obligations.
The Current ratio of MDCX (2.73) is worse than 67.10% of its industry peers.
A Quick Ratio of 2.73 indicates that MDCX has no problem at all paying its short term obligations.
The Quick ratio of MDCX (2.73) is worse than 65.07% of its industry peers.
Industry RankSector Rank
Current Ratio 2.73
Quick Ratio 2.73
MDCX Yearly Current Assets VS Current LiabilitesMDCX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 24.18% over the past year.
EPS 1Y (TTM)24.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.6%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 16.61% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y43.31%
EPS Next 2Y25.21%
EPS Next 3Y16.61%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MDCX Yearly EPS VS EstimatesMDCX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MDCX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MDCX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDCX Price Earnings VS Forward Price EarningsMDCX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDCX Per share dataMDCX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as MDCX's earnings are expected to grow with 16.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.21%
EPS Next 3Y16.61%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MDCX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MEDICUS PHARMA LTD

NASDAQ:MDCX (8/29/2025, 8:00:01 PM)

After market: 1.9405 +0 (+0.03%)

1.94

-0.06 (-3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)N/A N/A
Inst Owners19.2%
Inst Owner ChangeN/A
Ins Owners13.82%
Ins Owner Change11.71%
Market Cap36.32M
Analysts82.22
Price Target20.06 (934.02%)
Short Float %4.42%
Short Ratio1.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-68.45%
Min EPS beat(2)-76.47%
Max EPS beat(2)-60.43%
EPS beat(4)1
Avg EPS beat(4)-54%
Min EPS beat(4)-118.27%
Max EPS beat(4)39.15%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)63.89%
EPS NQ rev (1m)-1.41%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-48.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 10.4
P/tB 10.4
EV/EBITDA N/A
EPS(TTM)-1.87
EYN/A
EPS(NY)-0.87
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.19
TBVpS0.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -195%
ROE -319.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-358.98%
ROA(5y)-4285.53%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.73
Quick Ratio 2.73
Altman-Z -2.74
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.6%
EPS Next Y43.31%
EPS Next 2Y25.21%
EPS Next 3Y16.61%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-320.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-146.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-146.43%
OCF growth 3YN/A
OCF growth 5YN/A